Last day of trading in BTU and first day of trading with warrants of series TO 2

In June/July 2018, Phase Holographic Imaging PHI AB (“PHI”) conducted a rights issue of units in which the public also were given the opportunity to subscribe for units. Last day of trading in BTU (Paid Subscribed Unit) is August 16, 2018 and stop date is August 20, 2018. The company also announces that the first day of trading in warrants of series TO 2 is August 22, 2018.

Through the rights issue a total of 1 945 014 shares and 648 338 warrants of series TO 2 were issued. These have now been registered at the Swedish Companies Registration Office and are estimated to be distributed to each VP account/depot on August 22, 2018. After the registration of the rights issue at the Swedish Companies Registration Office, the total number of shares in PHI are 13 615 102 shares and the share capital amounts to 2 723 020.40 SEK. 

In addition to above, there are 648 338 outstanding warrants of series TO 2 that in May/June 2019 can provide PHI an additional approximately 18.3 million SEK before issue costs. Warrants of series TO 2 will be traded at Spotlight Stock Market. First day of trading in warrants of series TO 2 is August 22, 2018. The warrants have the ISIN-code SE0011308329 and will be traded under the ticker “PHI TO 2”.

FINANCIAL ADVISOR

Sedermera Fondkommission is the financial advisor to PHI in connection to the rights issue.

For information about the rights issue, please contact:
Sedermera Fondkommission
Tel: +46 40 615 14 10
E-mail: info@sedermera.se
Web: www.sedermera.se 

For additional information, please contact:
Peter Egelberg, CEO
Tel: +46 703 19 42 74
E-mail: ir@phiab.se
Web: www.phiab.se

Phase Holographic Imaging (PHI) leads the ground-breaking development of time-lapse cytometry instrumentation and software. With the first instrument introduced in 2011, the company today offers a range of products for long-term quantitative analysis of living cell dynamics that circumvent the drawbacks of traditional methods requiring toxic stains. Headquartered in Lund, Sweden, PHI trades through a network of international distributors. Committed to promoting the science and practice of time-lapse cytometry, PHI is actively expanding its customer base and scientific collaborations in cancer research, inflammatory and autoimmune diseases, stem cell biology, gene therapy, regenerative medicine and toxicological studies.